Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a
result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate
intratumoral T cell trafficking and persistence. Early (≤ 3 days) intratumoral presentation of
CAR T cells post-treatment is a superior predictor of survival than peripheral persistence.
Therefore, we have co-opted IL-8 release from tumors to enhance intratumoral T-cell
trafficking through a CAR design for maximal antitumor activity in solid tumors. Here, we …